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Abstract
Background: Th17 cells play a role in inflammation. Interleukin (IL)-10 is a potent anti-inflammatory cytokine.
However, it is poorly understood whether and how endogenous IL-10 impacts the development of Th17 cells in
human pathologies.
Materials and methods: We examined the relationship between IL-10 and Th17 cells in patients with Crohn’s
disease and in IL-10-deficient (IL-10-/-) mice. Th17 cells and dendritic cells (DCs) were defined by flow cytometry
and evaluated by functional studies.
Results: We detected elevated levels of IL-17 and Th17 cells in the intestinal mucosa of patients with Crohn’s
disease. Intestinal DCs from Crohn’s patients produced more IL-1b than controls and were superior to blood DCs in
Th17 induction through an IL-1-dependent mechanism. Furthermore, IL-17 levels were negatively associated with
those of IL-10 and were positively associated those of IL-1b in intestinal mucosa. These data point toward an in
vivo cellular and molecular link among endogenous IL-10, IL-1, and Th17 cells in patients with Crohn’s disease. We
further investigated this relationship in IL-10-/- mice. We observed a systemic increase in Th17 cells in IL-10-/- mice
when compared to wild-type mice. Similar to the intestinal DCs in patients with Crohn’s disease, murine IL-10-/-
DCs produced more IL-1b than their wild-type counterparts and promoted Th17 cell development in an IL-1-
dependent manner. Finally, in vivo blockade of IL-1 receptor signaling reduced Th17 cell accumulation and
inflammation in a mouse model of chemically-induced colitis.
Conclusions: Endogenous IL-10 constrains Th17 cell development through the control of IL-1 production by DCs,
and reaffirms the crucial anti-inflammatory role of IL-10 in patients with chronic inflammation.
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Introduction
Inflammation is associated with autoimmune diseases
and cancer development [1,2]. Recent studies have
emphasized the relevance of Th17 cell function in
human diseases, including multiple sclerosis [3], colitis
[4,5], psoriasis [6,7] and cancer [8,9]. It has been reported
that a variety of cytokine cocktails including transforming
growth factor beta (TGFb) and the interleukins (IL)-6,
IL-1, and IL-23 promote Th17 cell development [10-15],
whereas IL-2 inhibits Th17 cell development [16]. It is
generally accepted that these cytokines directly target T
cells, where they regulate the expression of certain tran-
scription factors and cytokine receptors, and affect Th17
cell development [17-19]. Importantly, however, effector
T helper (Th) cells are polarized by antigen-presenting
cells (APCs). The role of APC subsets including dendritic
cells (DCs) and macrophages has not been studied in the
development of Th17 cells in the microenvironment of
intestinal mucosa in patients with Crohn’s disease (CD).
In this study, we examined the effects of Crohn’s APCs
and the associated cytokines on Th17 cell induction in
patients with CD. We extended and confirmed our
human studies in mouse model with chemically-induced
intestinal inflammation.
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Furthermore, we extended and confirmed our human
studies in IL-10-deficient mouse model. IL-10-deficient
mice show enhanced development of several inflamma-
tory and autoimmune diseases [20], which partially mic-
mics patients with CD. It suggests that IL-10 may serve
a central function in vivo in restricting inflammatory
responses in patients with CD. In support of this possi-
bility, it was recently reported that a CD-associated
NOD2 mutation suppresses transcription of human IL-
10 by inhibiting activity of the nuclear ribonucleoprotein
hnRNP-A1, and low IL-10 expression is associated with
this mutation [21]. IL-10 is an immunosuppressive cyto-
kine that is produced by several cell types, including
myeloid APCs [22-25]. IL-10 often directly targets APCs
in an autocrine manner and impedes T cell activation
and polarization, thereby reducing inflammation
[22,23,26-29]. Thus, it is possible that IL-10 affects the
functionality of APCs, impacts Th17 cell development,
and Th17-associated human pathogeneses. Thus, we
assessed the role of APC-derived IL-10 in both patients
with CD and IL-10-/- mouse model, and investigated the
cellular and molecular relationship between IL-10 and
Th17 cells in these two systems. Notably, there is strong
genetic evidence that IL-23 plays a role in CD. IL-23
receptor polymorphisms were strongly associated with
susceptibility to CD in genome-wide scans [30]. An ele-
vation in transcripts encoding several inflammatory
cytokines including IL-6, IL-8, IL-17, IL-23 and TNFa is
detected in intestinal biopsies from individuals with
active CD [31]. On the basis of these results, clinical
studies have begun with anti-IL-12p40 (IL-23p40)
[32,33] or anti-IL-17 treatment in patients with autoim-
mune diseases including active CD [7]. Mixed clinical
responses are reported in a variety of autoimmune dis-
eases [7,32,33]. Our data demonstrate that endogenous
IL-10, likely derived from DCs, constrains Th17 cell
development through IL-1 in both scenarios. Our results
and current clinical trials demonstrate that several key
Th17-associated cytokines, rather than one specific cyto-
kine (IL-17 or IL-23), play important roles in human
autoimmunity. Thus, to engender reliable and efficient
clinical therapeutic efficacy, small molecules, monoclo-
nal antibodies and other recombinant receptor decoys
may be designed to simultaneously target multiple cru-
cial inflammatory mediators.
Materials and methods
Patients
Blood was collected from patients with Crohn’s disease
and healthy volunteers. Fresh colon tissues were collected
from patients with Crohn’s disease who underwent pro-
phylactic colonic resections or diagnostic biopsies. Fresh
“approximately normal” colon tissues adjacent to color-
ectal carcinoma were also collected as control tissues. All
patients with Crohn’s disease were in remission and were
not treated with steroid drugs or antibiological therapy
during the 2 months before the study. Patients involved
in the study were consented, and the study was approved
by local Institutional Review Boards.
Mice
6-12-week old female and male C57BL/6 wild-type, IL-
10-/-, and IL-1R-/- mice were purchased from the Jack-
son Laboratory and bred in-house. This research was
approved by the committee on Use and Care of Animals
at the University of Michigan.
IL-1Ra treatment
The human recombinant IL-1 receptor antagonist Ana-
kinra was administered at 150 mg/kg to mice intraperi-
toneally for 8 days. Mice not receiving Anakinra were
injected with PBS vehicle. For treatment of DSS-chal-
lenged mice, Anakinra administration (200 mg/kg)
began on the first day of the second cycle of DSS and
continued through the end of the experiment.
DSS treatment
Mice were treated with 3% DSS in water for 5 days, fol-
lowed by a rest period of 16 days during which they
were allowed free access to normal water. This treat-
ment was repeated for a total of two DSS cycles. Mice
were sacrificed at the end of the second rest period, and
their colons were jelly-rolled, formalin-fixed, and sub-
jected to hematoxylin and eosin (H&E) staining.
Flow cytometry analysis (FACS)
Single-cell suspensions were made from human and mouse
tissues. Cells were labeled with fluorescence-conjugated
antibodies to CD45, CD11c (both Invitrogen), CD90, CD4,
CD8, IL-17, FoxP3 (all eBioscience), and/or CD3 (BD Phar-
mingen). For cytokine profiles, the cells were stimulated,
stained and analyzed as previously published[26,34] with
FacsDIVA software (BD Biosciences).
Real-time reverse-transcriptase polymerase chain reaction
(RT-PCR)
Lin-CD11c+ cells (DCs) were isolated with a CD11c+
positive selection kit (StemCell Technologies, Vancou-
ver, British Columbia, Canada) and sorted from IL-10+/+
or IL-10-/- splenic cells and cultured with or without
LPS stimulation. In other experiments, fresh DCs (Lin-
CD11c+) or macrophages (CD14+) were isolated and
sorted from Crohn’s tissue, control colon tissue, or
blood. Cytokine transcripts were detected by real-time
RT-PCR as previously described [8]. Complementary
DNA was normalized against and expressed as the rela-
tive values to the house keeping gene gyceraldehyde-3-
phosphate dehydrogenase (GAPDH).
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T cell culture
Mouse spleen or human colon DCs and CD4+ T cells were
co-cultured in a ratio of 1:5 for 5-6 days with anti-CD3
and anti-CD28 antibodies. In other experiments, Crohn’s
T cells (1 × 106/ml) were activated for 40 hours with anti-
CD3 (5 ug/ml) and anti-CD28 (2.5 ug/ml). Colon tissue
cells (2 × 106/ml) from colon cancer patients were cul-
tured for 40 hours with medium or T cell supernatants in
the presence of anti-IL-17R antibody (R&D, clone 133617)
or isotype control. Cytokines in cell culture supernatants
were detected by ELISA.
ELISA cytokine detection
Supernatant was collected from culture with mouse T cells
and DCs, or LPS-activated DCs, or human colon lamina
propria or CD4+ T cells, or human colon cells and Crohn’s
T cells co-culture. In other experiments, fresh serum was
collected from the blood of healthy volunteers or Crohn’s
disease patients. Cytokines were detected using murine or
human DuoSet kits (R&D Systems, Minneapolis, MN).
Statistics
Experiments were evaluated using the Mann-Whitney or
Chi-squared test, with P < 0.05 considered significant. Sta-
tistics were performed in the GraphPad Prism program
suite (GraphPad Software, Inc., La Jolla, CA) and the Sta-
tistica program suite (StatSoft, Tulsa, OK).
Results
Increased IL-17 and Th17 cells in the intestine of patients
with Crohn’s disease
To investigate if intestinal T cells in patients with Crohn’s
disease (CD) included Th17 cells, we isolated the lamina
propria mononuclear cell fraction from fresh CD colonic
tissues or from “approximately normal” adjacent colonic
tissues in patients with colorectal cancer. We detected
higher levels of IL-17 in the supernatant of briefly cultured
CD lamina propria mononuclear cells than in the superna-
tant from control lamina propria cells (Figure 1a). This
indicates that IL-17 was spontaneously released in the cul-
tures of CD-associated immune cells. After a short stimu-
lation with IL-1 and IL-23, the levels of IL-17 were further
increased in cultures of lamina propria mononuclear cells
from CD patients and from control patients. However, the
levels of IL-17 were 15 times higher in patients with CD
than control (Figure 1a). Interestingly, limited levels of
IL-17 were detected in peripheral blood from healthy
controls, but were substantially increased in CD patients
(Figure 1b). Intracellular staining for IL-17 revealed that
IL-17 expression was in CD4+CD3+ cells. In line with the
data on IL-17 in culture supernatants (Figure 1a, b), the
numbers of Th17 cells and Foxp3+CD4+ regulatory T cells
were significantly higher in the CD colon tissues than in
peripheral blood and the colon tissue from non-CD
patients (Figure 1c). The data suggest that Th17 cells may
be induced in the local pathological environment in CD
patients.
Th17 cells are associated with reduced IL-10 and
increased IL-1 in CD patients
We next examined the potential mechanisms by which
Th17 cells were increased in the local CD environment.
IL-10 gene polymorphisms that result in defective IL-10
production are observed in patients with CD [21]. We
quantified IL-17 and IL-10 transcripts in mononuclear
lamina propria cells from patients with CD. The level of
IL-10 messages were negatively associated with those of
IL-17 (Figure 2a). We hypothesized that decreased IL-10
in CD patients may allow increased local concentrations
of cytokines associated with Th17 cell development.
Accordingly, we further quantified TGFb, IL-1a, IL-1b,
IL-6, and IL-23 in mononuclear lamina propria cells
from patients with CD. The levels of TGFb, IL-1a, IL-6,
and IL-23 were not associated with that of IL-10 (not
shown). To our surprise, we observed a significant nega-
tive association between IL-1b and IL-10 (Figure 2b).
Not surprisingly, however, was the observation that IL-
1b and IL-17 message levels correlated directly (Figure
2c). Given the importance of myeloid APC-derived IL-1
in the induction of human Th17 cells[8], we theorized
that myeloid APC subsets induced Th17 cells through
IL-1 in CD tissues. To test this hypothesis, we demon-
strated that both CD macrophages and myeloid dendri-
tic cells (DCs) spontaneously released IL-1b, and
stimulation with lipopolysaccharide (LPS) further
increased the levels of IL-1b (Figure 2d). However,
regardless of stimulation, Crohn’s intestinal DCs pro-
duced higher levels of IL-1b than Crohn’s intestinal
macrophages and normal intestinal DCs (Figure 2d).
This indicates that DCs from CD patients have an
increased potential to release IL-1b into the intestinal
milieu. Consistent with this, we observed that CD DCs
induced higher levels of T cell IL-17 production than
macrophages. Blockade of IL-1 receptor signaling
reduced CD4+ T cell-derived IL-17 production induced
by both DCs and macrophages (Figure 2e). The data
suggest that reduced IL-10 expression by intestinal DCs
may promote Th17 cell development through increased
IL-1 production in patients with CD.
Th17 cells promote inflammation in CD patients
Th17 cells may play a role in the pathogenesis of CD
[4,35-37]. To directly demonstrate the inflammatory
functionality of intestinal Th17 cells, we sorted and acti-
vated intestinal CD4+ T cells from patients with Crohn’s
disease. Fresh colon tissue cells were exposed to superna-
tants from activated CD T cells for a short time. In the
absence of CD T cell supernatant, colon tissue cells
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Figure 1 Th17 cells and IL-17 are increased in CD patient tissue. a) Lamina propria mononuclear cells from control colon tissues or CD
colons were cultured for two days with IL-1 and IL-23. Supernatants were subjected to ELISA for analysis of IL-17 protein. b) Serum from healthy
or CD patients was subjected to ELISA for IL-17 quantification. n = 16. *P < 0.0001. c) Healthy blood or control colon tissue or CD colon tissue
cells were stained with antibodies to CD3, CD4, IL-17, and FoxP3 and antigen expression was analyzed via FACS. Results are expressed as the
percent of IL-17+ or Foxp3+ T cells in the CD4+ T cells. The gates were on CD4+CD3+ T cells for both Th17 and Treg cells. n = 16.
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Figure 2 Relationships among IL-17, IL-1, and IL-10 in CD patients. a-c) IL-17, IL-10, and IL-1b message from fresh CD mononuclear lamina
propria cells were quantified via real-time PCR. Chi-squared (c2) test. P < 0.0001 for the following comparisons: IL-17 vs IL-10 (a), IL-1b vs IL-10
(b), and IL-17 vs IL-1b (c). n = 16. d) Crohn’s DCs expressed high levels of IL-1b. Crohn’s DCs and macrophages, and normal colon DCs were
cultured for 40 hours with or without LPS. Normal control DCs were isolated from normal colon tissues at least 5 cm away from colon cancer.
IL-1b protein was quantified via ELISA. n = 6. *, P < 0.005. e) Crohn’s DCs induced high levels of T cell-derived IL-17 production through IL-1.
CD4+ T cells were cultured for 48 hours with Crohn’s myeloid DCs or macrophages in the presence anti-IL-1R. IL-17 protein was detected via
ELISA in supernatants. n = 6. *, P < 0.005.
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produced minimal amounts of IL-1b (Figure 3a), IL-6
(Figure 3b), and IL-8 (Figure 3c). Interestingly, the levels
of IL-1b, IL-6, and IL-8 protein were dramatically
increased in the presence of CD T cell supernatants (Fig-
ure 3a-c). Blockade of IL-17 receptor (IL-17R) reduced
the production of IL-1b, IL-6, and IL-8 stimulated by CD
T cell supernatant (Figure 3a-c), suggesting that IL-17 is
at least partially responsible for the production of these
inflammatory cytokines. Human CD Th17 cells are there-
fore functional and may play an active pro-inflammatory
role in the local disease environment. Thus far, the
ex vivo and in vitro data support a cellular and molecular
link among IL-10, IL-1b, and Th17 cells in humans with
CD.
IL-10-/- murine DCs are superior Th17 cell inducers
IL-10-/- mice develop chronic enterocolitis, a condition
that shares many architectural signatures with human CD
[20]. These similarities include increased numbers of focal
ulcerations and transmural lesions, as seen in CD patients
[38]. To overcome the experimental limitations of
mechanism investigation using limited tissue from CD
patients, we extended our studies to the IL-10-/- mouse
model. We observed increased levels of Th17 cells in the
lymph nodes, spleen, blood, and intestines of IL-10-/- mice
as compared to wild-type (IL-10+/+) mice (Figure 4a, b).
There were no differences in other immune cell subsets,
including B cells, macrophages, DCs, granulocytes, and
natural killer cells between IL-10-/- and IL-10+/+ mice (not
shown). Thus, Th17 cells are spontaneously and systemi-
cally increased in IL-10-/- mice.
We next studied the potential underlying mechanisms
causing the spontaneous increase of Th17 cells in IL-
10-/- mice. To this end, IL-10+/+ and IL-10-/- spleen T
cells were cultured under Th17-polarizing conditions.
We observed that there were more Th17 cells in the IL-
10-/- cultures (Figure 4c) and more IL-17 in the IL-10-/-
culture supernatant when compared to IL-10+/+ cultures
(Figure 4d). To examine the cellular cause of the
increased Th17 cells, we investigated the role of IL-10-/-
DCs in Th17 cell induction. We co-cultured wild-type T
cells with wild-type DCs or IL-10-/- DCs, and examined
the resulting cellular phenotypes. We found increased
Th17 cells in co-cultures with IL-10-/- DCs as compared
to those with wild-type DCs (Figure 4e). Thus, similar
to human Crohn’s DCs, IL-10-/- mouse DCs are superior
inducers of Th17 cells.
IL-10-/- DCs induce Th17 cells through IL-1 in mice
We next examined possible reasons why murine IL-10-/-
DCs are better at Th17 cell induction. We and others
have demonstrated the importance of IL-1 in the devel-
opment of mouse and human Th17 cells[16,39]. Human
Crohn’s DCs produced more IL-1, and potently induced
Th17 cells (Figure 2d, e). We thus hypothesized that
mouse IL-10-/- DCs produce more IL-1 which in turn
leads to more potent Th17 induction. We first tested
this hypothesis in a co-culture system where wild-type
Figure 3 Crohn’s disease T cell-derived IL-17 stimulates the production of inflammatory cytokines. “Normal” colon tissue cells were
cultured for 40 hours with medium alone or CD T cell supernatants with or without anti-IL-17R. IL-1b (a), IL-6 (b), and IL-8 (c) were quantified in
supernatant. n = 5. *, P < 0.05 and **, P < 0.01.
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Figure 4 Murine IL-10-/- DCs are powerful Th17 inducers. a, b) Increased Th17 cells in IL-10-/- mice. Mononuclear cells from unchallenged IL-
10+/+ and IL-10-/- mouse organs were analyzed via FACS. a) Representative FACS plots. b) Results are expressed as the percentage of Th17 cells
in CD4+ T cell populations ± SEM. 6 mice/group, *P < 0.05. c, d). IL-10-/- spleen T cells were susceptible to Th17 polarization. IL-10+/+ and IL-10-/-
spleen T cells were polarized with Th17-polarizing cytokines for 6 days. Th17 cells were analyzed by FACS. c) Results are expressed as the
percentage of Th17 cells in CD4+ T cells. d) Supernatant from Th17 cultures was collected on day 3 and analyzed via ELISA for levels of IL-17. *P
< 0.05, average of three experiments. e) IL-10-/- DCs were potent Th17 inducers. IL-10+/+ CD4+ T cells were cultured with IL-10-/- or IL-10+/+
splenic DCs in a ratio of 5:1 for 5 days. Th17 cells were analyzed by FACS. Results are expressed as the percentage of Th17 cells in CD4+ T cells.
n = 6, *P < 0.05. Y axis showed SSC and the dot plots were gated on CD4+CD3+ T cells (a, c, e).
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DCs were incubated with either wild-type IL-1 receptor
(IL-1R+/+) or IL-1R-/- T cells. The resultant IL-1R-/- T
cell population expressing IL-17 was only half the size
of that in the IL-1R+/+ T cell cultures (Figure 5a). This
observation confirms the importance of IL-1 signaling in
Th17 development. In line with this finding, we
observed increased expression of IL-1a, IL-1b, IL-6, and
TNFa transcripts in IL-10-/- DCs when compared to
wild-type DCs (Figure 5b and not shown). Increased IL-
1b protein was also detected in LPS-stimulated IL-10-/-
DC culture supernatants (Figure 5c).
In order to determine whether this increased IL-1 was
involved in the stronger Th17 induction documented in
our experiments with IL-10-/- DCs, we added anti-IL-1R
to the co-cultures of T cells with IL-10+/+ or IL-10-/-
DCs. Blockade of IL-1R resulted in significantly
decreased Th17 cells in both cultures (Figure 5d) and
decreased IL-17 levels in culture supernatants (Figure
5e). These data indicate that IL-10-/- DCs may release
high levels of IL-1 and efficiently promote Th17 cell
development.
In vivo blockade of IL-1R signaling decreases Th17 cells
and reduces inflammation
Finally, we investigated whether in vivo blockade of IL-1
signaling had any impact on Th17 cell development. Initi-
ally, we administered the human recombinant IL-1R
antagonist (IL-1Ra) Anakinra, already shown to have effi-
cacy in mice [40], to IL-10+/+ and IL-10-/- mice and ana-
lyzed Th17 cells in different organs. As expected, in vivo
IL-1 blockade had no significant effect on Th17 cells in
wild-type mice (not shown), but decreased Th17 cells in
multiple compartments including lymph nodes, spleen,
and peripheral blood in IL-10-/- mice (Figure 6a). IL-10-/-
C57BL/6 mice usually do not develop colitis in pathogen-
free conditions. To evaluate the link among IL-1, IL-10,
and Th17 cells in an active inflammatory environment in
vivo, IL-1Ra was administered during the course of dex-
tran sodium sulfate (DSS)-induced colitis in IL-10-/- mice.
Similarly, we observed that IL-1Ra treatment decreased
Th17 cells in multiple organs, including the mesenteric
lymph nodes (mLN) (Figure 6b). More interestingly, Ana-
kinra-treated mice did not develop colon polyps, while
untreated mice did (Figure 6c). Grossly-evaluated colons
from untreated mice exhibited more inflammation and
blood vessel involvement than Anakinra-treated mice (Fig-
ure 6d). Hematoxylin and eosin (H&E)-stained sections of
mouse colons showed that Anakinra-treated mice had
lower inflammatory infiltrate than untreated mice (Figure
6e). These data demonstrate that IL-1 signaling blockade
reduces Th17 cells and ameliorates chemically-induced
inflammation. Our work therefore demonstrates a potent
cellular and molecular link between IL-10 and Th17 cells
in mice and in humans with Crohn’s disease.
Discussion
In the present study, we established a cellular and molecu-
lar relationship among IL-1, IL-10, and Th17 cell develop-
ment in inflammatory disease models in humans and
mice. This link may be important in the regulation of
immune pathogenesis of human chronic inflammatory
conditions, including CD.
Th17 cells play a role in the inflammatory response
associated with multiple human autoimmune diseases
[4,41-43] and cancer [8,9]. Th17 cells and/or IL-17 are
detected in CD patients [35-37,44-48]. However, the gen-
eration and functional relevance of Th17 cells remains
poorly understood in CD patients. We have tested the
functionality of fresh CD Th17 cells, and found that these
T cells induce the production of IL-1, IL-6, and IL-8 by
colon tissue cells through IL-17 in vitro. It suggests that
these cells may mediate or/and accelerate local inflamma-
tion by inducing inflammatory cytokine production. In
line with this, elevated inflammatory cytokines are
detected in the freshly isolated colon environment from
patients with CD. It has been reported that recombinant
IL-17 induces IL-6 expression in other systems [49-52]. As
IL-1, IL-6, and IL-8 play crucial roles in CD [53-57], it is
likely that Th17 cells promote the production of inflam-
matory cytokines and contribute to the immunopathogen-
esis of CD in patients. Notably, although IL-17, as a
signature gene for Th17 cells, importantly attributes to
Th17 cell biology, it is well appreciated that Th17 cell biol-
ogy may depend on the synergistic effects between Th17-
associated cytokines, rather than IL-17 alone [8,58]. For
example, IL-17 and IFNg synergistically induce b-defensin
expression in patients with psoriasis [6] and Th1-type che-
mokine production in patients with cancer [8]. This may
partially explain why IL-17 signaling blockade generates
variable clinical benefits in patients with psoriasis, rheuma-
toid arthritis, and uveitis [7] and minimal clinical response
in patients with CD.
We have demonstrated a cellular and molecular link
among IL-10, IL-1, and Th17 cells in patients with CD
and in IL-10-/- mice. In CD patients, the levels of intest-
inal IL-10 are negatively associated with IL-17 and IL-1.
Both IL-10-/- mouse DCs and human Crohn’s DCs are
superior inducers of Th17 cells via their increased IL-1
production. Blockade of the IL-1 signaling pathway
reduces Th17 cell development both in vitro and in vivo.
In agreement with these observations, we and others
have shown that IL-1 is crucial for inducing Th17 cells in
humans and mice [16,59]. In patients with psoriasis,
psoriatic DCs potently induce Th17 cells in an IL-1-
dependent manner [6]. Human tumor-associated macro-
phages also promote Th17 cell development through IL-
1 [8]. IL-1 has been shown to induce gastric inflamma-
tion and is associated gastric carcinoma [1]. Notably, IL-
10 suppresses IL-1 production [60,61] and that IL-1 is
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Figure 5 Mouse IL-10-/- DCs induce Th17 cells through the IL-1/IL-1R signaling pathway. a) Reduced Th17 cells in DC-stimulated IL-1R-/-
CD4+ T cell cultures. IL-1R-/- or IL-1R+/+ CD4+ T cells were stimulated with wild-type DCs for 5 days. The cells were analyzed for Th17. n = 3. b,
c)IL-10-/- DCs expressed high levels of IL-1. IL-10+/+ or IL-10-/- DCs were cultured with or without LPS for 8 (b) or 48 hours (c). IL-1a and IL-1b
message was quantified via real-time PCR (b). IL-1b protein was detected in culture supernatant via ELISA (c). *P < 0.05, average of 3
experiments. d, e) Blockade of IL-1R reduced DC-mediated Th17 induction. IL-10-/- or IL-10+/+ DCs were cultured in a ratio of 1:5 with IL-10+/+
CD4+ T cells with or without anti-IL-1R. The cells were analyzed on day 5 for Th17. Results are expressed as the percentage of Th17 cells in CD4+
T cells (d). IL-17 was detected in culture supernatants on day 3 via ELISA. Results are expressed as the mean values ± SEM (e). n = 4. *, P < 0.05.
Y axis showed SSC and the dot plots were gated on CD4+CD3+ T cells (a, d).
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Figure 6 In vivo IL-1R blockade reduces Th17 cells and inflammation. a) In vivo IL-1R blockade decreased homeostatic Th17 cells. Mice
were treated with Anakinra or PBS for 7 days. Single-cell suspensions from different organs were analyzed for Th17 cells. Results are expressed
as the percentage of Th17 cells in CD4+ T cells ± SEM. *P < 0.05, 5 mice/group. b) In vivo IL-1R blockade reduced DSS-induced Th17 cells. Mice
were treated with DSS to induce inflammation and given Anakinra throughout the second cycle of treatment. Single-cell suspensions from
different organs were analyzed for Th17 cells. Results are shown as the percentage of Th17 cells in mensenteric lymph node CD4+ T cells in
mice treated with Anakinra or PBS. Y axis showed SSC and the dot plots were gated on CD4+CD3+ T cells. n = 4. c-e) In vivo IL-1R blockade
prevented polyp formation and ameliorated inflammation induced by DSS. Colon polyps were counted in DSS-challenged IL-10-/- mice treated
with PBS or Anakinra (IL-1Ra). n = 8 mice per group, *P < 0.05 (c). Bloody and polyp-carrying colon sections from untreated mice (top) are
shown, but were not observed in IL-1Ra-treated mice (bottom) (d). H&E staining showed heavy cellular infiltration in colon tissue from untreated
mice (top), but not in colon tissue from IL-1Ra-treated mice (bottom) (e).
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involved in controlling Th17 cells in the mouse model of
experimental autoimmune encephalomyelitis (EAE) [39].
Exogenous IL-10 can suppress the in vitro development
of Th17 cells from CD4+ T cells in patients with rheuma-
toid arthritis [62]. However, our study is the first to
demonstrate a role for IL-10 in Th17 development
through the control of IL-1 expression by DCs in both
mouse and human systems, including CD patients. In
support of our studies in patients with CD, one recent
report demonstrates that mouse Th17 cells expressed
interleukin-10 receptor a (IL-10Ra) in vivo. Importantly,
T cell specific blockade of IL-10 signaling led to a selec-
tive increase of Th17 cells during intestinal inflammation
in the small intestine in mice. Furthermore, in this
mouse model, Treg cells were able to control Th17 cells
in an IL-10-dependent manner in vivo. Thus IL-10 sig-
naling directly suppresses Th17 cells [63]. However, high
levels of Treg cell infiltration are detected in patients
with CD and ulcerative colitis [64]. Although Treg cells
inhibit Th17 cells in patients with cancer [8], it appears
that human Treg cells failed doing so in the microenvir-
onments of chronic graft-versus-host disease (GVHD),
ulcerative colitis, and inflammation-associated colon can-
cer [9,64]. It is possible that human Th17 cells have stem
cell features and are resistant to apoptosis in the chronic
inflammatory microenvironments [9,64]. Nonetheless,
our data indicate that IL-1 plays a key role in Th17 cell
development in human autoimmune disease, and support
the notion that IL-1 signaling blockade is a potential
strategy to treat patients with these conditions. IL-10, via
its downregulation of IL-1, is thus able to limit develop-
ment of Th17 cells in mice and humans, and in doing so
executes some of its anti-inflammatory effects.
The next logical step is to investigate how IL-10 con-
trols IL-1 production by APCs. IL-10 dampens MyD88-
dependent signaling in DCs and leads to LPS hypore-
sponsiveness [65]. Because IL-1 signaling can be
mediated by MyD88, this may explain how IL-10 controls
endotoxin-induced IL-1 production. It is also possible
that IL-10 controls IL-1 expression machinery, such as
IL-1 converting enzyme (ICE) and components of the
inflammasome [66,67]. However, it remains to be deter-
mined if IL-10 suppresses IL-1 production induced by
other stimuli, including the necrotic tissue often found in
a chronic inflammatory environment. The key question
remaining is why IL-10 production is reduced in some
CD patients. A nucleotide-binding oligomerization
domain containing 2 (NOD2) mutation commonly
observed in CD patients may lead to inhibition of IL-10
transcription [21]. However, we have not examined the
gene profile of NOD expression in our patient popula-
tions. Since 30% of CD patients have NOD mutations, it
is likely that alterations in NOD2 transcription may at
least partially contribute to the reduced IL-10 production
in our patient tissues. The data further suggests that IL-
10 therapy or IL-1 signaling blockade may not be gener-
ally meaningful for all the CD patients.
In summary, we have demonstrated that IL-10 targets
APCs, and suppresses Th17 cell development in mice and
humans through modulation of IL-1 production. The data
document a cellular and molecular link among IL-10, IL-
1, and Th17 cells, and suggest that IL-10 may inhibit
inflammation via control of Th17 cell development.
Conclusions
To date, it is well accepted that Th17 cells play a role in
inflammation including Crohn’s disease. Our studies
have demonstrated that IL-1 drives the immune effector
status towards IL-17, and dendritic cell-derived IL-10
constraints Th17 cell development through IL-1 in
patients with CD. This is the first report demonstrating
cellular and molecular mechanistic link among IL-1, IL-
10 and Th17 cells in patients with CD. This link is func-
tionally examined in mouse model. Demonstration of
the novel mechanistic interplay between inflammatory
and anti-inflammatory elements increases our under-
standing of CD pathogenesis and can identify novel
pathways involved in disease aetiology.
Abbreviations
Th: T-helper; Treg: regulatory T; IL: interleukin; APC: antigen-presenting cell;
DC: dendritic cell; Crohn’s disease: CD.
Acknowledgements
We thank Deborah Postiff and Monica Muzzin in the tissue procurement
core for their technical assistance. This research is supported (in part) by
NIH/NCI R01 grants (CA099985, CA0156685, CA152470) and the NIH through
the University of Michigan’s Cancer Center Support Grant (5 P30 CA46592).
Author details
1Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
2Graduate Program in Immunology, University of Michigan, Ann Arbor, MI,
USA. 3Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
4Department of Medicine, Renji Hospital, Shanghai Jiao-Tong University,
Shanghai, P. R. China. 5University of Michigan Comprehensive Cancer Center,
Ann Arbor, MI, USA. 6Graduate Program in Cancer Biology, Ann Arbor, MI,
USA.
Authors’ contributions
CMW, LW, IK and SW performed experiments. EH, JK and WZ obtained
funding, provided material and intellectual support. CMW and WZ wrote the
paper. All authors read and approved the final manuscript. CMW, LW and
SW contributed equally to this work.
Competing interests
The authors declare that they have no competing interests.
Received: 11 August 2011 Accepted: 16 December 2011
Published: 16 December 2011
References
1. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-
Oesterreicher M, Bjorkdahl O, Fox JG, Wang TC: Overexpression of
interleukin-1beta induces gastric inflammation and cancer and mobilizes
myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14:408-419.
2. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860-867.
Wilke et al. Journal of Translational Medicine 2011, 9:217
http://www.translational-medicine.com/content/9/1/217
Page 11 of 13
3. Du C, Liu C, Kang J, Zhao G, Ye Z, Huang S, Li Z, Wu Z, Pei G: MicroRNA
miR-326 regulates TH-17 differentiation and is associated with the
pathogenesis of multiple sclerosis. Nat Immunol 2009, 10:1252-1259.
4. Kleinschek MA, Boniface K, Sadekova S, Grein J, Murphy EE, Turner SP,
Raskin L, Desai B, Faubion WA, de Waal Malefyt R, et al: Circulating and
gut-resident human Th17 cells express CD161 and promote intestinal
inflammation. J Exp Med 2009, 206:525-534.
5. Kryczek I WK, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, Greenson J,
Chang A, Roliński J, Radwan P, Fang J, Wang G, Zou W: IL-17+ Regulatory
T Cells in the Microenvironments of Chronic Inflammation and Cancer.
Journal of Immunology 2011.
6. Kryczek I, Bruce AT, Gudjonsson JE, Johnston A, Aphale A, Vatan L,
Szeliga W, Wang Y, Liu Y, Welling TH, et al: Induction of IL-17+ T cell
trafficking and development by IFN-gamma: mechanism and
pathological relevance in psoriasis. J Immunol 2008, 181:4733-4741.
7. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C,
Draelos Z, Gold MH, Durez P, et al: Effects of AIN457, a fully human
antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and
uveitis. Sci Transl Med 2010, 2:52ra72.
8. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E,
Finlayson E, Simeone D, Welling TH, et al: Phenotype, distribution,
generation, and functional and clinical relevance of Th17 cells in the
human tumor environments. Blood 2009, 114:1141-1149.
9. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A,
Lange A, Zou W: Human TH17 Cells Are Long-Lived Effector Memory
Cells. Sci Transl Med 2011, 3:104ra100.
10. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFbeta in
the context of an inflammatory cytokine milieu supports de novo
differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
11. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL,
Kuchroo VK: Reciprocal developmental pathways for the generation of
pathogenic effector TH17 and regulatory T cells. Nature 2006,
441:235-238.
12. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO,
Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-
beta induces development of the T(H)17 lineage. Nature 2006,
441:231-234.
13. Nakae S, Iwakura Y, Suto H, Galli SJ: Phenotypic differences between Th1
and Th17 cells and negative regulation of Th1 cell differentiation by IL-
17. J Leukoc Biol 2007, 81:1258-1268.
14. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B,
Blumenschein WM, McClanahan TK, O’Shea JJ, Cua DJ: The interleukin 23
receptor is essential for the terminal differentiation of interleukin 17-
producing effector T helper cells in vivo. Nat Immunol 2009, 10:314-324.
15. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, Blank RB,
Meylan F, Siegel R, Hennighausen L, et al: Interleukin-2 signaling via
STAT5 constrains T helper 17 cell generation. Immunity 2007, 26:371-381.
16. Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W: Cutting
Edge: Opposite Effects of IL-1 and IL-2 on the Regulation of IL-17+ T
Cell Pool IL-1 Subverts IL-2-Mediated Suppression. J Immunol 2007,
179:1423-1426.
17. Dong C: TH17 cells in development: an updated view of their molecular
identity and genetic programming. Nat Rev Immunol 2008, 8:337-348.
18. Kolls JK, Linden A: Interleukin-17 family members and inflammation.
Immunity 2004, 21:467-476.
19. Ouyang W, Kolls JK, Zheng Y: The biological functions of T helper 17 cell
effector cytokines in inflammation. Immunity 2008, 28:454-467.
20. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient
mice develop chronic enterocolitis. Cell 1993, 75:263-274.
21. Noguchi E, Homma Y, Kang X, Netea MG, Ma X: A Crohn’s disease-
associated NOD2 mutation suppresses transcription of human IL10 by
inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat
Immunol 2009, 10:471-479.
22. Vicari AP, Trinchieri G: Interleukin-10 in viral diseases and cancer: exiting
the labyrinth? Immunol Rev 2004, 202:223-236.
23. O’Garra A, Murphy KM: From IL-10 to IL-12: how pathogens and their
products stimulate APCs to induce T(H)1 development. Nat Immunol
2009, 10:929-932.
24. Enk AH, Katz SI: Identification and induction of keratinocyte-derived IL-
10. J Immunol 1992, 149:92-95.
25. Jung HC, Eckmann L, Yang SK, Panja A, Fierer J, Morzycka-Wroblewska E,
Kagnoff MF: A distinct array of proinflammatory cytokines is expressed in
human colon epithelial cells in response to bacterial invasion. J Clin
Invest 1995, 95:55-65.
26. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M,
Cheng P, Curiel T, Myers L, et al: B7-H4 expression identifies a novel
suppressive macrophage population in human ovarian carcinoma. J Exp
Med 2006, 203:871-881.
27. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R,
Knutson KL, Daniel B, Zimmermann MC, et al: Blockade of B7-H1 improves
myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003,
9:562-567.
28. Zou W, Chen L: Inhibitory B7-family molecules in the tumour
microenvironment. Nat Rev Immunol 2008, 8:467-477.
29. Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A: Interleukin-10 and
the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
30. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ,
Steinhart AH, Abraham C, Regueiro M, Griffiths A, et al: A genome-wide
association study identifies IL23R as an inflammatory bowel disease
gene. Science 2006, 314:1461-1463.
31. Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G,
Salo H, Rasanen L, Kolho KL, Farkkila M, Savilahti E, Vaarala O: IL-23/IL-17
immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis 2008,
14:1175-1184.
32. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B,
Goodman N, Groden C, Hornung RL, et al: Anti-interleukin-12 antibody for
active Crohn’s disease. N Engl J Med 2004, 351:2069-2079.
33. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S,
Johanns J, Blank M, Rutgeerts P: A randomized trial of Ustekinumab, a
human interleukin-12/23 monoclonal antibody, in patients with
moderate-to-severe Crohn’s disease. Gastroenterology 2008, 135:1130-1141.
34. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-
Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al: Specific recruitment
of regulatory T cells in ovarian carcinoma fosters immune privilege and
predicts reduced survival. Nat Med 2004, 10:942-949.
35. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B,
Parente E, Fili L, Ferri S, Frosali F, et al: Phenotypic and functional features
of human Th17 cells. J Exp Med 2007, 204:1849-1861.
36. Rovedatti L, Kudo T, Biancheri P, Sarra M, Knowles CH, Rampton DS,
Corazza GR, Monteleone G, Di Sabatino A, Macdonald TT: Differential
regulation of interleukin 17 and interferon gamma production in
inflammatory bowel disease. Gut 2009, 58:1629-1636.
37. Bogaert S, Laukens D, Peeters H, Melis L, Olievier K, Boon N, Verbruggen G,
Vandesompele J, Elewaut D, De Vos M: Differential mucosal expression of
Th17-related genes between the inflamed colon and ileum of patients
with inflammatory bowel disease. BMC Immunol 2010, 11:61.
38. Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, Thompson-
Snipes L, Leach MW, Rennick D: Enterocolitis and colon cancer in
interleukin-10-deficient mice are associated with aberrant cytokine
production and CD4(+) TH1-like responses. J Clin Invest 1996,
98:1010-1020.
39. Sutton C, Brereton C, Keogh B, Mills KH, Lavelle EC: A crucial role for
interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate
autoimmune encephalomyelitis. J Exp Med 2006, 203:1685-1691.
40. Surguladze D, Deevi D, Claros N, Corcoran E, Wang S, Plym MJ, Wu Y,
Doody J, Mauro DJ, Witte L, et al: Tumor necrosis factor-alpha and
interleukin-1 antagonists alleviate inflammatory skin changes associated
with epidermal growth factor receptor antibody therapy in mice. Cancer
Res 2009, 69:5643-5647.
41. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M,
Giuliani F, Arbour N, Becher B, Prat A: Human TH17 lymphocytes promote
blood-brain barrier disruption and central nervous system inflammation.
Nat Med 2007, 13:1173-1175.
42. Melton AC, Bailey-Bucktrout SL, Travis MA, Fife BT, Bluestone JA,
Sheppard D: Expression of alphavbeta8 integrin on dendritic cells
regulates Th17 cell development and experimental autoimmune
encephalomyelitis in mice. J Clin Invest 2010, 120:4436-4444.
43. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S: Type 17 T helper
cells-origins, features and possible roles in rheumatic disease. Nat Rev
Rheumatol 2009, 5:325-331.
Wilke et al. Journal of Translational Medicine 2011, 9:217
http://www.translational-medicine.com/content/9/1/217
Page 12 of 13
44. Nielsen OH, Kirman I, Rudiger N, Hendel J, Vainer B: Upregulation of
interleukin-12 and -17 in active inflammatory bowel disease. Scand J
Gastroenterol 2003, 38:180-185.
45. Saruta M, Yu QT, Avanesyan A, Fleshner PR, Targan SR, Papadakis KA:
Phenotype and effector function of CC chemokine receptor 9-expressing
lymphocytes in small intestinal Crohn’s disease. J Immunol 2007,
178:3293-3300.
46. Beltran CJ, Candia E, Erranz B, Figueroa C, Gonzalez MJ, Quera R,
Hermoso MA: Peripheral cytokine profile in Chilean patients with Crohn’s
disease and ulcerative colitis. Eur Cytokine Netw 2009, 20:33-38.
47. Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S,
Jurgens M, Schmechel S, Konrad A, et al: Role of the novel Th17 cytokine
IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F
expression in active Crohn’s disease and analysis of the IL17F p.
His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008, 14:437-445.
48. Hovhannisyan Z, Treatman J, Littman DR, Mayer L: Characterization of IL-
17-producing regulatory T cells in inflamed intestinal mucosa from
patients with inflammatory bowel diseases. Gastroenterology 2010.
49. Laan M, Cui ZH, Hoshino H, Lotvall J, Sjostrand M, Gruenert DC, Skoogh BE,
Linden A: Neutrophil recruitment by human IL-17 via C-X-C chemokine
release in the airways. J Immunol 1999, 162:2347-2352.
50. Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y, Okuno T,
Fujiyama Y, Bamba T: IL-17 stimulates inflammatory responses via NF-
kappaB and MAP kinase pathways in human colonic myofibroblasts. Am
J Physiol Gastrointest Liver Physiol 2002, 282:G1035-1044.
51. Shimada M, Andoh A, Hata K, Tasaki K, Araki Y, Fujiyama Y, Bamba T: IL-6
secretion by human pancreatic periacinar myofibroblasts in response to
inflammatory mediators. J Immunol 2002, 168:861-868.
52. Andoh A, Takaya H, Makino J, Sato H, Bamba S, Araki Y, Hata K, Shimada M,
Okuno T, Fujiyama Y, Bamba T: Cooperation of interleukin-17 and
interferon-gamma on chemokine secretion in human fetal intestinal
epithelial cells. Clin Exp Immunol 2001, 125:56-63.
53. Pallone F, Monteleone G: Mechanisms of tissue damage in inflammatory
bowel disease. Curr Opin Gastroenterol 2001, 17:307-312.
54. McCormack G, Moriarty D, O’Donoghue DP, McCormick PA, Sheahan K,
Baird AW: Tissue cytokine and chemokine expression in inflammatory
bowel disease. Inflamm Res 2001, 50:491-495.
55. Murata Y, Ishiguro Y, Itoh J, Munakata A, Yoshida Y: The role of
proinflammatory and immunoregulatory cytokines in the pathogenesis
of ulcerative colitis. J Gastroenterol 1995, 30(Suppl 8):56-60.
56. Baumgart DC, Carding SR: Inflammatory bowel disease: cause and
immunobiology. Lancet 2007, 369:1627-1640.
57. Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects
and established and evolving therapies. Lancet 2007, 369:1641-1657.
58. Zou W, Restifo NP: T(H)17 cells in tumour immunity and immunotherapy.
Nat Rev Immunol 2010, 10:248-256.
59. Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, Ma L,
Watowich SS, Jetten AM, Tian Q, Dong C: Critical regulation of early Th17
cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
60. Kawachi S, Jennings S, Panes J, Cockrell A, Laroux FS, Gray L, Perry M, van
der Heyde H, Balish E, Granger DN, et al: Cytokine and endothelial cell
adhesion molecule expression in interleukin-10-deficient mice. Am J
Physiol Gastrointest Liver Physiol 2000, 278:G734-743.
61. Toth LA, Opp MR: Cytokine- and microbially induced sleep responses of
interleukin-10 deficient mice. Am J Physiol Regul Integr Comp Physiol 2001,
280:R1806-1814.
62. Heo YJ, Joo YB, Oh HJ, Park MK, Heo YM, Cho ML, Kwok SK, Ju JH, Park KS,
Cho SG, et al: IL-10 suppresses Th17 cells and promotes regulatory T
cells in the CD4+ T cell population of rheumatoid arthritis patients.
Immunol Lett 2010, 127:150-156.
63. Huber S, Gagliani N, Esplugues E, O’Connor W Jr, Huber FJ, Chaudhry A,
Kamanaka M, Kobayashi Y, Booth CJ, Rudensky AY, et al: Th17 cells express
interleukin-10 receptor and are controlled by Foxp3 and Foxp3+
regulatory CD4+ T cells in an interleukin-10-dependent manner.
Immunity 2011, 34:554-565.
64. Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, Greenson J,
Chang A, Rolinski J, et al: IL-17(+) regulatory T cells in the
microenvironments of chronic inflammation and cancer. J Immunol 2011,
186:4388-4395.
65. Chang J, Kunkel SL, Chang CH: Negative regulation of MyD88-dependent
signaling by IL-10 in dendritic cells. Proc Natl Acad Sci USA 2009,
106:18327-18332.
66. Fantuzzi G, Dinarello CA: Interleukin-18 and interleukin-1 beta: two
cytokine substrates for ICE (caspase-1). J Clin Immunol 1999, 19:1-11.
67. Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform
triggering activation of inflammatory caspases and processing of proIL-
beta. Mol Cell 2002, 10:417-426.
doi:10.1186/1479-5876-9-217
Cite this article as: Wilke et al.: Endogenous interleukin-10 constrains
Th17 cells in patients with inflammatory bowel disease. Journal of
Translational Medicine 2011 9:217.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Wilke et al. Journal of Translational Medicine 2011, 9:217
http://www.translational-medicine.com/content/9/1/217
Page 13 of 13
